Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias

Clinical Cancer Research

Volumn 18, Issue 24, 2012, Pages 6723-6731

  Karp, Judith E ^a   Thomas, Brian M ^b   Greer, Jacqueline M ^a   Sorge, Christopher ^c   Gore, Steven D ^a   Pratz, Keith W ^a   Smith, B Douglas ^a   Flatten, Karen S ^d   Peterson, Kevin ^d   Schneider, Paula ^d   Mackey, Karen ^a   Freshwater, Tomoko ^c   Levis, Mark J ^a   McDevitt, Michael A ^a,b   Carraway, Hetty E ^a   Gladstone, Douglas E ^a   Showel, Margaret M ^a   Loechner, Sabine ^c   Parry, David A ^c,e   Horowitz, Jo Ann ^c   Isaacs, Randi ^c,f   Kaufmann, Scott H ^d   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d MAYO CLINIC   (United States)

^e Portola Pharmaceuticals   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 1; CYTARABINE; ENZYME INHIBITOR; HISTONE H2AX; SCH 900776; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BLAST CELL CRISIS; BONE MARROW BIOPSY; CANCER RECURRENCE; CANDIDEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTINUOUS INFUSION; CYTOKINE RELEASE SYNDROME; DNA DAMAGE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG HALF LIFE; ENZYME ACTIVATION; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; INFECTIOUS COMPLICATION; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QT PROLONGATION; SIDE EFFECT; TUMOR BIOPSY; TUMOR LYSIS SYNDROME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CYTARABINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTONES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRAZOLES; PYRIMIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84871234067     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2442     Document Type: Article

References (35)

1. Lowenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, et al. Cytarabine dose for acute myeloid leukemia. New Engl J Med 2011;364:1027-36.
2. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005:106:1154-63. (Pubitemid 41130866)
3. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998;58:4349-57. (Pubitemid 28450036)
4. Huang M, Wang Y, Collins M, Gu JJ, Mitchell BS, Graves LM. Inhibition of nucleoside transport by p38 MAPK inhbiitiors. J Biol Chem 2002;277:28364-7. (Pubitemid 41079256)
5. Liliemark JO, Plunkett W, Dikxon DO. Relationship of 1-beta-D- arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5′-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res 1985;45:5952-7. (Pubitemid 16218617)
6. Karp JE, Donehower RC, Dole GB, Burke PJ. Correlation of drug-perturbed marrow cell growth kinetics and intracellular 1-beta-D-arabinofuranosylcytosine with clinical response in adult acute myelogenous leukemia. Blood 1987;69:1134-40. (Pubitemid 17080936)
7. Kimball AP, Wilson MJ. Inhibition of DNA polymerase by beta-D-arabinosylcytosine and reversal of inhibition by deoxycytidine-5′- triphosphate. Proc Soc Exp Biol Med 1968;127:429-32.
8. Momparler RL. Effect of cytosine arabinoside 5′-triphosphate onmammalian DNA polymerase. Biochem Biophys Res Commun 1969;34:464-71.
9. Graham FL, Whitmore GF. Studies in mouse L-cells on the incorporation of 1-beta-D arabinofuranosylcytosine 5′-triphosphatase. Cancer Res 1970;30:2636-44.
10. Kufe DW, Major PP, Egan EM, Beardsley GP. Correlation of cytotoxicity with incorporation of ara-C in DNA. J Biol Chem 1980;225:8897-900.
11. Major PP, Egan EM, Beardsley GP, Minden MD, Kufe DW. Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA. Proc Natl Acad Sci U S A 1981;78:3235-9. (Pubitemid 11032022)
12. Ewald B, Sampath D, Plunkett W. ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance. Cancer Res 2008;68:7947-55.
13. Zou L, Elledge SJ. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 2003;300:1542-8. (Pubitemid 36682880)
14. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 2010;16:376-83.
15. Feijoo C, Hall-Jackson C, Wu R, Jenkins D, Leitch J, Gilbert DM, et al. Activation ofmammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing. J Cell Biol 2001;154:913-23. (Pubitemid 34286172)
16. Zachos G, Rainey MD, Gillespie DAF. Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects. EMBO J 2003;22:713-23. (Pubitemid 36193615)
17. Shimuta K, Nakajo N, Uto K, Hayano Y, Okazaki K, Sagata N. Chk1 is activated transiently and targets Cdc25A fior degradation at the Xenopus midblastula transition. EMBO J 2002;21:3694-703. (Pubitemid 34787043)
18. Zhao H, Watkins JL, Piwnica-Worms H. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci U S A 2002;99:14795-800. (Pubitemid 35334563)
19. Loegering D, Arlander SAH, Hackbarth J, Vroman B, Lieberman HB, Karnitz LM, et al. Rad9 protects cells from topoisomerase poison-induced cell death. J Biol Chem 2004;279:18641-7. (Pubitemid 38623286)
20. Mesa RA, Loegering D, Powell HL, Flatten K, Arlander SAH, Dai NT, et al. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood 2005;106:318-27. (Pubitemid 40967208)
21. Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 2001;21:4129-39. (Pubitemid 32565295)
22. Cho SH, Toouli CD, Fuji GH, Crain C, Parry D. Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell cycle 2005;4:131-9. (Pubitemid 41038942)
23. Wang S, Wang Z, Grant S. Bryostatin 1 and UCN-01 potentiate 1-B-D-arabinofuranosylcytosine- induced apoptosis in human myeloid leukemia cells through disparate mechanisms. Mol Pharmacol 2003;63:232-42. (Pubitemid 36043827)
24. Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, et al. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha 1-acid glycoprotein. Cancer Res 1998;58:3248-52.
25. Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001;19:2319-33. (Pubitemid 32366984)
26. Ruegg UT, Burgess GM. Staurosporine, K252 and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends Pharmacol Sci 1989;10:218-20. (Pubitemid 19146392)
27. Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. Oncogene 2003;22:6609-20. (Pubitemid 37372341)
28. Arlander SJ, Eapen AK, Vroman BT, McDonald RJ, Toft DO, Karnitz LM. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem 2003;278:52572-7. (Pubitemid 38035854)
29. Kaufmann SH, Karp JE, Litzow MR, Mesa RA, Hogan W, Steensma DP, et al. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica 2011;96:1619-26.
30. Schenk EL, Koh BD, Flatten KS, Peterson KL, Parry D, Hess AD, et al. Effects of selective checkpoint kinase I inhibition on cytarabine cytotoxicity in acute myelogenous leukemia. Clin Cancer Res 2012;18:5364-73.
31. Guzi TJ, Paruch K, Dwyer MP, Labroli M, Shanahan F, Davis N, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther 2011;10:591-602.
32. Karp JE, Smith BD, Resar LS, Greer JM, Blackford A, Zhao M, et al. Phase I and pharmacokinetic study of bolus-infusion flavopiridol follwed by cytosine arabinoside and mitoxantrone for acute leukemia. Blood 2011;117:3302-10.
33. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-74.
34. Cavelier C, Didier C, Prade N, Mansat-De Mas V, Manenti S, Recher C, et al. Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy. Cancer Res 2009;69:8652-61.
35. Didier C, Demur C, Grimal F, Jullien D, Manenti S, Ducommon B. Evaluation of checkpoint kinase targeting therapy in acute myeloid leukemia with complex karyotype. Cancer Biol Ther 2012;13:307-13.